Advertisement
Organisation › Details
Orphazyme A/S (Nasdaq Copenhagen: ORPHA.CO)
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). *
Start | 2009-06-01 established | |
Group | Orphazyme (Group) | |
Predecessor | Orphazyme ApS | |
Industry | enzyme replacement therapeutic | |
Industry 2 | DRUGS, ORPHAN | |
Person | Stratton, Kim (Centogene 202202– CEO before Orphazyme + Shire Pharmaceuticals + Novartis) | |
Person 2 | Vadsholt, Anders (TopoTarget 201011 CFO) | |
Region | København (Copenhagen) | |
Country | Denmark | |
Street | 3 Ole Maaløes Vej | |
City | 2200 Copenhagen N | |
Tel | +45-39-178272 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Centogene AG. (5/9/18). "Press Release: Centogene Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease". Rostock. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Orphazyme (Group)
- [1] Centogene N.V.. (6/27/22). "Press Release: Centogene Announces Appointment of Miguel Coego Rios as Chief Financial Officer". Cambridge, MA, Rostock & Berlin....
- [2] Centogene N.V.. (2/1/22). "Press Release: Centogene Announces Nomination of Kim Stratton as Chief Executive Officer". Cambridge, MA, Rostock & Berlin....
- [3] Leo Pharma A/S. (1/31/22). "Press Release: Leo Pharma Appoints Christophe Bourdon as New CEO". Ballerup....
- [4] Orphazyme A/S. (9/29/20). "Press Release: Orphazyme Prices Its Global Offering, Consisting of an Initial Public Offering of ADSs in the U.S. and a Concurrent Private Placement of Ordinary Shares in Europe". Copenhagen....
- [5] Orphazyme A/S. (2/7/20). "Press Release: Orphazyme Completes Offering of 7,032,937 Shares in a Directed Issue and Private Placement and Raises approximately DKK 745,000,000 (EUR 100 Million / USD 110 Million) [Not for US, CA, JP or AU]". Copenhagen....
- [6] Orphazyme A/S. (1/30/19). "Press Release: Orphazyme Reports Positive Results from Full Data Set of Phase II/III Arimoclomol Tria in Niemann-Pick Disease Type C (NPC)". Copenhagen....
- [7] Centogene AG. (5/9/18). "Press Release: Centogene Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease". Rostock....
- [8] Orphazyme ApS. (3/8/17). "Press Release: Orphazyme Raises EUR 14 Million to Further Expand Its Clinical Development Programme"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top